PCOS and Visceral Fat: Causes and Treatments

PCOS and visceral fat are closely linked through a cycle of insulin resistance and elevated androgens that promotes abdominal fat accumulation. Visceral fat, the metabolically active fat surrounding internal organs, is not simply a cosmetic concern in polycystic ovary syndrome. It actively worsens hormonal imbalance, amplifies symptoms such as irregular periods and hirsutism, and raises long-term cardiovascular risk. Understanding why PCOS makes visceral fat harder to shift, and what evidence-based strategies can help, is essential for anyone managing this condition.

Why does PCOS make it easier to gain visceral fat?

PCOS promotes visceral fat gain primarily through insulin resistance and elevated androgens, both of which favour abdominal fat storage. Insulin resistance, present in up to 70 per cent of people with PCOS, causes chronically high insulin that inhibits fat breakdown in visceral depots.

Polycystic ovary syndrome (PCOS) promotes visceral fat accumulation primarily through insulin resistance and elevated androgens, both of which are associated with fat storage towards the abdomen rather than the hips and thighs. Visceral fat is the metabolically active fat that surrounds the internal organs, and it behaves differently from subcutaneous fat stored just beneath the skin.

PCOS presents across a spectrum of phenotypes, and not everyone with the condition has marked hyperandrogenism. Where androgens are elevated, however, the ovaries and adrenal glands produce excess androgens such as testosterone. Higher androgen levels are associated with a more android, or apple-shaped, fat distribution pattern, meaning fat tends to deposit around the waist and abdomen. This is distinct from the gynoid pattern more typical in women without PCOS.

Insulin resistance is estimated to affect around 50 to 70 per cent of people with PCOS, a figure cited in NICE guidance on PCOS (NG194) and on the NHS PCOS information pages. When cells respond poorly to insulin, the pancreas compensates by secreting more of it. Chronically elevated insulin promotes fat storage and inhibits fat breakdown, particularly in visceral depots. The result is that even modest caloric surpluses can translate into disproportionate abdominal fat gain in people with PCOS.

Hormonal disruption in PCOS has also been associated with changes in appetite-regulating hormones such as leptin and ghrelin, though the evidence in PCOS populations is still developing and individual responses vary. Together, these mechanisms create a biological environment in which visceral fat can accumulate more readily, which is why PCOS-related weight gain often feels disproportionate to dietary intake.

How does visceral fat make PCOS symptoms worse?

Visceral fat secretes inflammatory cytokines that deepen insulin resistance and stimulate ovarian androgen production, worsening irregular periods, acne, hirsutism and fertility difficulties. It also raises cardiovascular risk markers including blood pressure, triglycerides and LDL cholesterol.

Visceral fat actively worsens PCOS symptoms by secreting inflammatory cytokines and adipokines that amplify insulin resistance and androgen production, creating a self-reinforcing cycle. Unlike subcutaneous fat, visceral fat is metabolically active and functions almost like an endocrine organ in its own right.

Inflammatory molecules released by visceral fat, including tumour necrosis factor-alpha and interleukin-6, are thought to impair insulin signalling in muscle and liver cells, based on evidence from endocrinology reviews and studies in PCOS cohorts. This deepens insulin resistance, which in turn drives the ovaries to produce more androgens. Higher androgens then promote further visceral fat deposition, closing the loop.

From a symptom perspective, this cycle has several practical consequences:

• Irregular periods: Elevated androgens and insulin disrupt the hormonal signals needed for regular ovulation, making cycles more erratic.

• Acne and hirsutism: Greater androgen exposure worsens skin oiliness and unwanted hair growth.

• Fertility difficulties: Anovulation becomes more frequent as the hormonal environment deteriorates.

• Mood and energy: Chronic low-grade inflammation associated with visceral fat is linked to fatigue, and systematic reviews indicate that depression and anxiety are more prevalent in people with PCOS than in the general population.^[10]

Visceral fat also raises cardiovascular risk markers, including blood pressure, triglycerides and LDL cholesterol, which is clinically significant because PCOS itself is already associated with a higher long-term cardiovascular risk. There is also an association between visceral adiposity in PCOS and metabolic dysfunction-associated steatotic liver disease (MASLD, previously called NAFLD), and a GP can advise on monitoring if this is a concern.^[20]

Addressing visceral fat is therefore not simply a cosmetic concern but a meaningful part of managing PCOS-related health outcomes.

The link between insulin resistance, hormones, and belly fat

Insulin resistance is the central mechanism linking hormonal imbalance and visceral fat in PCOS: high insulin stimulates ovarian androgen production, lowers SHBG, and inhibits lipolysis in visceral depots. Cortisol further compounds this by promoting abdominal fat deposition and worsening insulin resistance.

Insulin resistance is the central mechanism connecting hormonal imbalance and visceral fat accumulation in PCOS, and understanding this link explains why standard dietary advice alone often produces limited results. When muscle, liver and fat cells become less responsive to insulin, blood glucose rises and the pancreas secretes compensatory amounts of insulin to maintain control.

High circulating insulin is understood to have a stimulatory effect on the ovarian theca cells, prompting them to produce excess androgens, particularly testosterone and androstenedione.^[15][16] These androgens suppress sex hormone-binding globulin (SHBG), a protein that normally binds testosterone and keeps it inactive. Lower SHBG means more free, biologically active testosterone circulates in the blood, intensifying androgenic symptoms. These mechanisms are described in endocrine society reviews on PCOS pathophysiology.

At the same time, elevated insulin inhibits lipolysis, the process by which fat cells release stored fatty acids for energy. Visceral fat depots are particularly sensitive to this effect. The liver also responds to high insulin by increasing production of very-low-density lipoprotein (VLDL) particles, contributing to the dyslipidaemia commonly seen in PCOS.

Cortisol, the stress hormone, adds another layer of complexity. Evidence suggests that elevated cortisol promotes visceral fat deposition and can worsen insulin resistance, and chronic stress is common in people managing a long-term condition such as PCOS. This means that psychological wellbeing is not separate from metabolic health in PCOS but is directly intertwined with it. Addressing insulin resistance through lifestyle, and where appropriate medication, therefore has downstream benefits for androgen levels, menstrual regularity and visceral fat distribution simultaneously.

Can you reduce visceral fat if you have PCOS?

Yes, visceral fat can be reduced in PCOS through lifestyle changes that target insulin resistance, such as reducing refined carbohydrates and increasing aerobic activity. NICE NG194 notes that 5 to 10 per cent weight loss produces meaningful improvements in insulin sensitivity and androgen levels.

Yes, visceral fat can be reduced in people with PCOS. Visceral fat tends to respond to lifestyle intervention, and NICE guidance on PCOS (NG194) notes that even modest reductions of 5 to 10 per cent of body weight are associated with meaningful improvements in insulin sensitivity, androgen levels and menstrual regularity.

The key is that interventions need to address the underlying insulin resistance rather than simply restricting calories. Approaches that lower insulin levels, such as reducing refined carbohydrate intake and increasing physical activity, are particularly effective at targeting visceral depots. Research consistently shows that aerobic exercise can reduce visceral fat independently of changes in total body weight, making it a valuable tool even when the scales do not move significantly.^[17][18]

For people with PCOS, the timeline for seeing results may be longer than in people without the condition, and progress can feel slower due to the hormonal environment. This is a physiological reality rather than a failure of effort, and it is important that healthcare professionals frame expectations accordingly.

Where lifestyle changes alone are insufficient, medical treatment may be appropriate. A GP or specialist can assess whether medications such as metformin, which improves insulin sensitivity, or weight-management medicines are suitable. Weight-management medicines, including GLP-1 receptor agonists and tirzepatide, are not recommended during pregnancy or breastfeeding, and anyone of reproductive age should discuss contraception and pre-conception planning with their prescriber before starting treatment. If you experience suspected side effects from any medicine, you can report these to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where clinically appropriate options may be considered alongside lifestyle guidance.

Regular monitoring of waist circumference, rather than weight alone, is a useful way to track visceral fat changes, as it reflects abdominal adiposity more directly than body mass index. NICE obesity guidance suggests that, for people of white European background, a waist circumference above 94 cm in men and above 80 cm in women indicates increased risk, with higher risk above 102 cm and 88 cm respectively.^[2] Lower thresholds apply for people of South Asian, Chinese, Japanese and other ethnic backgrounds; a GP or practice nurse can advise on the appropriate threshold and correct measurement technique for you.

Which treatments does the NHS offer for PCOS-related weight gain?

NHS treatments include metformin for insulin resistance, GLP-1 receptor agonists such as semaglutide and tirzepatide for weight management (subject to ICB eligibility), and orlistat. Referral to dietitian support or specialist weight-management services is also available via a GP.

The NHS offers several treatment options for PCOS-related weight gain, with the approach tailored to the individual's symptoms, metabolic profile and reproductive goals. NICE guidance NG194 (Polycystic ovary syndrome: diagnosis and management) recommends that weight management be addressed as a core component of PCOS care, given its impact on both metabolic and reproductive outcomes.

Metformin is the most commonly prescribed medication for insulin resistance in PCOS. It is not licensed specifically for weight loss, but NICE NG194 recommends its use in PCOS for metabolic features including insulin resistance, and it may support modest weight reduction and is particularly useful in people with impaired glucose tolerance.^[1][4] It is available on the NHS for this purpose.

Combined oral contraceptives are often prescribed to regulate periods and reduce androgen-related symptoms such as acne and hirsutism. They do not directly target visceral fat but can improve the hormonal environment.

GLP-1 receptor agonists, such as semaglutide (Wegovy) and liraglutide (Saxenda), are MHRA-authorised for chronic weight management.^[7] Tirzepatide (Mounjaro) is also MHRA-authorised in the UK for both type 2 diabetes and chronic weight management.^[5][6] NHS access to these medicines depends on local Integrated Care Board (ICB) commissioning decisions and the eligibility criteria set out in the relevant NICE technology appraisals. Access typically occurs through NHS specialist tiered weight-management services (tier 2, 3 or 4), and a GP can advise on local referral pathways.

Orlistat is another licensed weight-management option available on the NHS and may be considered where other approaches are not suitable.

Referral pathways may include dietitian support, structured weight-management programmes, or endocrinology review for complex cases. A GP is the appropriate first point of contact for anyone with PCOS who is concerned about weight gain or metabolic health, and they can coordinate onward referral where needed.

What lifestyle changes actually work for visceral fat in PCOS?

A combination of aerobic exercise, resistance training and a low glycaemic index diet has the strongest evidence for reducing visceral fat in PCOS. At least 150 minutes of moderate-intensity aerobic activity per week is recommended by UK Chief Medical Officers' guidelines.

The lifestyle changes with the strongest evidence for reducing visceral fat in PCOS are a combination of regular aerobic exercise, resistance training, and a dietary pattern that moderates insulin spikes, rather than any single intervention in isolation. Evidence reviewed by NICE and published in peer-reviewed endocrinology literature consistently supports a combined approach.

Exercise recommendations:

• Aerobic activity: The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic exercise per week, such as brisk walking, cycling or swimming.^[8][9] Studies in PCOS populations support this level of activity for reductions in visceral fat, even without significant weight loss.

• Resistance training: Building muscle mass improves insulin sensitivity and increases resting metabolic rate, both of which support visceral fat reduction over time.

• High-intensity interval training (HIIT): Some studies suggest HIIT may be effective at reducing visceral adiposity in women with PCOS, though the evidence base is still developing and individual tolerance varies.^[18][20] It may be a useful option for those who find sustained moderate-intensity exercise difficult to maintain.

Dietary approaches:

• A lower glycaemic index (GI) diet, which prioritises wholegrains, legumes, vegetables and lean protein over refined carbohydrates and sugary foods, helps moderate post-meal insulin surges.

• Reducing ultra-processed food intake and added sugars is broadly recommended.

• There is no single diet proven superior for PCOS, but consistency and sustainability matter more than strict adherence to any named plan.

• Referral to a registered dietitian can be helpful for personalised guidance; a GP can arrange this through NHS services.

Sleep and stress management are often overlooked but are clinically relevant. Poor sleep raises cortisol and ghrelin, both of which are associated with visceral fat accumulation. Mindfulness-based stress reduction and cognitive behavioural therapy (CBT) have shown promise for improving psychological wellbeing in PCOS, and some studies suggest benefits for metabolic markers, though this evidence should be regarded as preliminary and these approaches are best used alongside, not instead of, physical and dietary interventions.^[21][22]

Anyone with PCOS who is struggling to make progress despite lifestyle changes should speak to their GP rather than assuming the approach is wrong, as underlying insulin resistance may warrant additional medical support.

Scientific References

1. Polycystic ovary syndrome (NG194): diagnosis and management.
2. Overweight and obesity management (NG246): Identifying and assessing overweight, obesity and central adiposity.
3. Polycystic ovary syndrome: treatment summary – BNF/NICE.
4. Polycystic ovary syndrome: metformin in women not planning pregnancy (ESUOM6).
5. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
6. Tirzepatide (Mounjaro) – NHS medicines information.
7. First GLP-1 tablet for weight loss approved in the UK (semaglutide).
8. Physical activity guidelines: UK Chief Medical Officers' report.
9. Physical activity guidelines for adults aged 19 to 64 – NHS.
10. Infante-Cano M et al. The prevalence and risk of anxiety and depression in women with PCOS: meta-analysis. 2025..
11. Cartier A et al. Visceral obesity and plasma glucose-insulin homeostasis. 2008..
12. Adipose-androgen crosstalk in polycystic ovary syndrome: mechanisms and therapeutic implications. 2025..
13. Impact of Sodium Butyrate Supplementation on Insulin Resistance and Adipose Tissue Modulation in Murine Models of PCOS. 2025..
14. van Bree BE et al. Sex hormone-binding globulin as a biomarker for PCOS. 2025..
15. Obesity-induced infertility and hyperandrogenism are corrected by deletion of the insulin receptor in the ovarian theca cell. 2014..
16. Hyperinsulinemia amplifies GnRH agonist stimulated ovarian steroid secretion in women with PCOS. 2012..
17. Effects of exercise on insulin resistance and body composition in overweight and obese women with and without PCOS. 2011..
18. The Effect of Exercise on Reproductive and Metabolic Outcomes in Women With PCOS: A Systematic Review and Meta-Analysis. 2025..
19. Nestler JE et al. Restoration of reproductive potential by lifestyle modification in obese PCOS. 1999..
20. Physical activity, sedentary behavior, and metabolic-reproductive health in women with PCOS: a narrative review. 2025..
21. Integrating evidence-based lifestyle and adjunct therapies for long-term management of PCOS. 2025..
22. The role of meditation and mindfulness in the management of PCOS: a scoping review. 2024..
23. Mindfulness-based stress reduction for overweight/obese women with and without PCOS: design and methods of a pilot RCT. 2015..

Frequently Asked Questions